The Uromigos
Episodes
Episode 92: Second line therapy in advanced RCC
09 Apr 2021
Contributed by Lukas
Viktor Grünwald discusses treatment for progression of disease after front lines PD1 based therapy.
Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer
26 Mar 2021
Contributed by Lukas
Joaquim Bellmunt describes this study as well as adjuvant nivolumab and ctDNA in bladder cancer.
Episode 90: The Uromigos Podcast with QOL Expert David Cella
12 Mar 2021
Contributed by Lukas
Everything you wanted to know about quality of life assessment in cancer but were too afraid to ask.
Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer
04 Mar 2021
Contributed by Lukas
David McDermott describes these back to back JCO publications.
Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler
26 Feb 2021
Contributed by Lukas
In these podcasts, we explore academic career development with individuals in different stages of their career.
Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal
26 Feb 2021
Contributed by Lukas
In these podcasts, we explore academic career development with individuals at different stages in their career.
Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein
26 Feb 2021
Contributed by Lukas
In these podcasts, we explore academic career development with individuals in different stages of their career.
Episode 85: The CLEAR Trial
14 Feb 2021
Contributed by Lukas
Toni Choueiri discusses the phase three results
Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney
13 Feb 2021
Contributed by Lukas
Chris explores the prostate cancer programme.
Episode 83: Is cabozantinib the new standard of care in papillary renal cancer?
13 Feb 2021
Contributed by Lukas
Monty Pal discusses his randomised phase 2 study in papillary renal cancer.
Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer?
13 Feb 2021
Contributed by Lukas
Eric Jonash gives a thoughtful answer to this issue.
Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130
13 Feb 2021
Contributed by Lukas
These new data are important as it is the setting where these agents are currently recommended, but we have not seen the data in this specific subset ...
Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial
13 Feb 2021
Contributed by Lukas
Neil Shore presents the impressive updates for the results of this trial.
Episode 79: Adjuvant nivolumab in operable urothelial cancer
13 Feb 2021
Contributed by Lukas
Matt Galski discusses this potentially practice-changing study.
Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer
12 Feb 2021
Contributed by Lukas
Arjun Balar discusses these studies and the impact they will have.
Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC
06 Feb 2021
Contributed by Lukas
Stephen Boorjian outlines his recent Lancet oncology paper. Tom and Brian struggle to keep up.
Episode 76: Tom Hutson discusses lenvatinib and everolimus
22 Jan 2021
Contributed by Lukas
Discussion on lenvatinib and everolimus prior to the CLEAR trial presentation.
Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal
14 Jan 2021
Contributed by Lukas
Silke, Chris and Bertrand discuss bone protective therapy and bone targeted therapy.
Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza
11 Jan 2021
Contributed by Lukas
Nick James and Chris Sweeney debate this issue. Tom and Silke try to keep things on track.
Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano
08 Jan 2021
Contributed by Lukas
Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer.
Episode 72: Uromigos Christmas Special - Renal cancer year in review
21 Dec 2020
Contributed by Lukas
Laurence Albiges discusses renal cancer highlights from the year.
Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky
18 Dec 2020
Contributed by Lukas
Matt discusses the year in review, including first line and adjuvant immune therapy studies, ADCs and FGFR targeting are also discussed.
Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan
11 Dec 2020
Contributed by Lukas
A review of the year in prostate cancer with Chuck Ryan.
Episode 69: Testis Cancer Christmas Special: 2020 year in review
09 Dec 2020
Contributed by Lukas
Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020.
Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell
08 Dec 2020
Contributed by Lukas
Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one poi...
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer
17 Nov 2020
Contributed by Lukas
David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.
Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer
09 Nov 2020
Contributed by Lukas
Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer.
Episode 65: Review of the International Kidney Cancer Symposium
02 Nov 2020
Contributed by Lukas
Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and...
Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC
28 Oct 2020
Contributed by Lukas
'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debat...
Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer
09 Oct 2020
Contributed by Lukas
Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer.
Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo
06 Oct 2020
Contributed by Lukas
A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer.
Episode 61: Nick James discusses the latest update of the STAMPEDE study
21 Sep 2020
Contributed by Lukas
Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data.
Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer
21 Sep 2020
Contributed by Lukas
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.&nbs...
Episode 59: Ipatercertib in biomarker positive castrate resistant prostate cancer
20 Sep 2020
Contributed by Lukas
Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC. A positive R3 trial in the ESMO plenary session.
Episode 58: Brilliant ESMO discussant Richard Cathomas talks to Brian and Tom about the meaning of DANUBE and KN362
19 Sep 2020
Contributed by Lukas
The group go into the detail of chemo immune combinations and what to do next.
Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer
19 Sep 2020
Contributed by Lukas
The group attempts to put the data into context with the other available combinations.
Episode 56: Matt Galsky and Tom Powles discuss ESMO 2020 immune therapy data in bladder cancer
19 Sep 2020
Contributed by Lukas
The group try to get to the bottom of whether these data has made any difference in treatment and future plans.
Episode 55: The Uromigos Paper of the Month - Cabozantinib in Bladder Cancer by Dr. Andrea Apolo
31 Aug 2020
Contributed by Lukas
Andrea talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer.
Episode 54: Biomarkers in prostate cancer with Chris Sweeney
24 Jul 2020
Contributed by Lukas
Some thought it would never come - the final podcast of the World Tour from Boston.
Episode 53: Still in Boston - biomarkers in bladder cancer
24 Jul 2020
Contributed by Lukas
Tom, Brian and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer.
Episode 52: The Final Stop - Boston: David McDermott discusses biomarkers in renal cancer in the era of immune therapy
24 Jul 2020
Contributed by Lukas
Tom, David and Brian discuss biomarkers in renal cancer in the era of immune therapy.
Episode 51: The Uromigos World Tour is in Norway with Jan Oldenburg - discussing key topics in testis cancer
18 Jul 2020
Contributed by Lukas
Jan Oldenburg from Norway discusses treatment choices for stage 1 testis cancer, the dilemma of high dose therapy for relapse and long term toxicity o...
Episode 50: The Uromigos World Tour in London with renal cancer surgery
15 Jul 2020
Contributed by Lukas
Axel Bex talks about small renal masses, robotic vs partial nephrectomy and surgery in metastatic disease.
Episode 49: The Tour remains in Germany with Oliver Grimm and renal cancer
14 Jul 2020
Contributed by Lukas
The World Tour stays in Germany to discuss the first line renal cancer (clear cell and non-clear cell) and clinical trials with Oliver Grimm.
Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer
10 Jul 2020
Contributed by Lukas
Jürgen discusses German research and surgery for bladder cancer. The podcast ends abruptly - which was not his fault!
Episode 46: The Uromigos World Tour in Spain discussing SOGUG and Renal Cancer with Cristina Suarez
09 Jul 2020
Contributed by Lukas
Cristina Suarez discusses the success of clinical trials in Spain, and access to treatments.
Episode 45: The Uromigos World Tour arrives in Japan
03 Jul 2020
Contributed by Lukas
Yoshi Tomita explains treatment pathways and research in GU cancer in Japan. Brian explains why he likes Japan so much.
Episode 44: The Uromigos World Tour in Australia - Talking with Ian Davis about prostate cancer and ANZUP
03 Jul 2020
Contributed by Lukas
Ian Davis discusses why ANZUP has been so successful, and the EnzaMet study. An uninvited guest arrives towards the end.
Episode 43: The Uromigos World Tour in Singapore with Ravi Kanesvaran
29 Jun 2020
Contributed by Lukas
Ravi describes treatment pathways and research for Southeast Asia in GU cancer.
Episode 42: The Uromigos in Argentina
28 Jun 2020
Contributed by Lukas
Juan Sade discusses research, treatment pathways in GU cancer, steak and red wine in Argentina.
Episode 41: The Uromigos World Tour lands in Brazil - Fernando Maluf talks about prostate cancer and recent research in Brazil
25 Jun 2020
Contributed by Lukas
The tour lands in sunny Brazil with a trip to a Japanese restaurant and a discussion about research and prostate cancer.
Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib
22 Jun 2020
Contributed by Lukas
The Uromigos World Tour moves to Paris. Treatment for tumours that progress after first line immunetherapy is discussed. The role of Tivozanib is a fo...
Episode 39: The Uromigos World Tour - Renal Cancer and IMDC Risk with Danny Heng in Calgary
18 Jun 2020
Contributed by Lukas
Danny discusses Italian food and the past, present and future of the IMDC prognostic score.
Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC
16 Jun 2020
Contributed by Lukas
Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field.
Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg
01 Jun 2020
Contributed by Lukas
Everything you wanted to know about FGFR inhibition but were afraid to ask.
Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
01 Jun 2020
Contributed by Lukas
Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1)
31 May 2020
Contributed by Lukas
Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO.
Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough?
30 May 2020
Contributed by Lukas
Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret.
Episode 33: Adjuvant Atezolizumab in Urothelial Cancer
29 May 2020
Contributed by Lukas
Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field.
Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020
29 May 2020
Contributed by Lukas
Thomas Hope is quizzed on the results of his study presented at ASCO20.
Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer
29 May 2020
Contributed by Lukas
Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease.
Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)
29 May 2020
Contributed by Lukas
Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds.
Episode 29: PSMA PET at ASCO 2020 with Mike Morris
29 May 2020
Contributed by Lukas
Mike Morris presents the findings in his prospective study.
Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer
29 May 2020
Contributed by Lukas
Eric Jonasch discusses his ASCO presentation, which shows significant activity of HIF targeting in renal cancer patients with VHL syndrome.
Episode 27: COVID-19 in > 1000 Cancer Patients with Jeremy Warner (CCC-19)
29 May 2020
Contributed by Lukas
Jeremy Warner summarises the recent Lancet paper describing the outcome of cancer patients with COVID-19.
Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020
19 May 2020
Contributed by Lukas
Joaquim Bellmunt talks about management of muscle invasive bladder cancer prior to the Atezolizumab adjuvant data at ASCO20.
Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial
19 May 2020
Contributed by Lukas
Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial.
Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality
28 Apr 2020
Contributed by Lukas
Marina Garassino and Leora Horn discuss their AACR study of COVID-19 in lung cancer.
Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer
28 Apr 2020
Contributed by Lukas
Chris Sweeney explains why the trial was negative and answers some of the questions.
Episode 22: COVID-19 and Cardiovascular Disease
22 Apr 2020
Contributed by Lukas
Kaushik Amancherla and Javid Moslehi discuss the link of COVID-19 and cardiovascular disease. Professor Tom Powles and Dr. Brian Rini struggle to keep...
Episode 21: Treating cancer patients over the next year in the era of COVID-19
15 Apr 2020
Contributed by Lukas
The Uromigos struggle to describe what cancer care looks like in three months’ time during the COVID-19 pandemic.
Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection
15 Apr 2020
Contributed by Lukas
The Uromigos can’t agree on how to approach COVID-infected GU cancer patients who need systematic treatment.
Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer
15 Apr 2020
Contributed by Lukas
Professor Monty Pal discusses non-clear cell renal cancer while Dr. Brian Rini gets irritated by background interruptions.
Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns
06 Apr 2020
Contributed by Lukas
Dena Battle presents a 500-patient survey on issues around COVID-19. Professor Tom Powles and Dr. Brian Rini attempt to address the issues raised.
Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19
02 Apr 2020
Contributed by Lukas
Professor Tom Powles, Dr. Brian Rini and Dr. Toni Choueiri discuss the evolving landscape in Boston, and meetings such as ASCO and ESMO in 2020.
Episode 16: Treatments and Trials for COVID-19
31 Mar 2020
Contributed by Lukas
Professor Nick Mark discusses the latest data on drug treatments and trials for COVID-19.
Episode 15: COVID-19 and Bladder Cancer Surgery
28 Mar 2020
Contributed by Lukas
The Uromigos discuss the practicalities in surgery for bladder cancer in the era of COVID-19 with Betsy Plimack (Fox Chase Cancer Center, Philadelphia...
Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle
24 Mar 2020
Contributed by Lukas
Dr. Brian Rini and Professor Tom Powles discuss the data and ongoing studies with the IL-6 antibody tocilizumab.
Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials
23 Mar 2020
Contributed by Lukas
Dr. David Boulware discusses existing data and ongoing prophylaxis studies.
Episode 12: COVID-19 in Cancer Patients - The Seattle Experience
20 Mar 2020
Contributed by Lukas
A discussion with doctors from the Fred Hutchinson Cancer Center in Seattle about COVID-19.
Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer
16 Mar 2020
Contributed by Lukas
Chuck Drake and Doug Johnson discuss possible risk benefits of immune checkpoint inhibitors during the COVID-19 pandemic.
Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective
16 Mar 2020
Contributed by Lukas
Dena Battle (President, KCCure) asks key patient-focused questions about kidney cancer management during the COVID-19 pandemic.
Episode 9: COVID-19 and Cancer: An International Perspective
16 Mar 2020
Contributed by Lukas
Five members of the groups from Europe and North America discuss the current situation for cancer patients.
Episode 8: COVID-19 and Cancer Patients
13 Mar 2020
Contributed by Lukas
Professor Tom Powles and Dr. Brian Rini discuss the virus with an expert, Ronan Breen.
Episode 7: The First Uromigos Prostate Cancer Podcast
27 Feb 2020
Contributed by Lukas
Silke Gillessen and Chris Sweeney discuss how data from recent ESMO and GU ASCO meetings has changed the way they treat prostate cancer.
Episode 6: Urothelial Cancer Highlights from ASCO GU 2020
26 Feb 2020
Contributed by Lukas
In this episode, Professor Tom Powles and Dr. Brian Rini talk to Dr. Kala Sridhar about key developments in urothelial cancer presented at ASCO GU 202...
Episode 5: Renal Highlights from ASCO GU 2020
24 Feb 2020
Contributed by Lukas
Professor Tom Powles and Dr. Brian Rini broadcast from ASCO GU 2020, San Francisco.
Episode 4: Treatment Choices in Front Line Advanced Renal Cancer
11 Feb 2020
Contributed by Lukas
Dr. Brian Rini and Professor Tom Powles ask David McDermott about how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab intreatment opt...
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer
11 Feb 2020
Contributed by Lukas
Guests Dr. Arjun Balar and Professor Seth Lerner give an overview of the recent FDA approval of pembrolizumab in this indication to Professor Tom Powl...
Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer
11 Feb 2020
Contributed by Lukas
Matthew Galski and Petros Grivas engage in a discussion with Professor Tom Powles and Dr. Brian Rini about IMVIGOR130.
Episode 1: Introduction to Uromigos Podcasts
11 Feb 2020
Contributed by Lukas
Professor Tom Powles and Dr. Brian Rini discuss the purpose of the podcasts and how to complain if you don’t like them